Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Sarcoma 3Stomach Neoplasms 2Sarcoma, Synovial 2Neuroendocrine Tumors 2Liposarcoma 2Glioblastoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Brain Neoplasms 2Bone Neoplasms 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Thymus Neoplasms 1Testicular Neoplasms 1Skin Neoplasms 1Sarcoma, Kaposi 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1

Interventions

Temozolomide 32Radiotherapy 11Magnetic Resonance Spectroscopy 11Carboplatin 10Bevacizumab 10Irinotecan 9Carmustine 9Filgrastim 8Erlotinib Hydrochloride 8Surgical Procedures, Operative 7sargramostim 5Imatinib Mesylate 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5temsirolimus 4Vorinostat 4Sirolimus 4Procarbazine 4Peripheral Blood Stem Cell Transplantation 4O(6)-benzylguanine 4aldesleukin 3Thalidomide 3Iodine-125 3Immunohistochemistry 3Gadolinium DTPA 3Cyclophosphamide 3Bortezomib 3Biopsy 3lonafarnib 2imetelstat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × Quality of Life × Sarcoma × Clear all
NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡